Post-embolization Syndrome Following Yttrium-90 Radiation Segmentectomy

Vanani, Naisarg B; Janardan, Abhishek; Asmi, Nisar; Jha, Pinky

doi:10.7759/cureus.35947

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immediately after the procedure, patients may experience post embolization syndrome (PES) which is comprised of an array of symptoms including abdominal pain or discomfort, nausea, vomiting, and fatigue. PES is usually self-limiting and treatment is supportive [22]. Radiation-induced liver disease (RILD) is one of the most feared adverse events related to TARE and occurs in less than 2% of the cases [23].…”

Section: Safety and Efficacy Of Tarementioning

confidence: 99%

Role of Transarterial Radioembolization in Management of HCC

Badar,

Husnain,

Fung

et al. 2024

Liver Cirrhosis and Its Complications - Advances in Diagnosis and Management

View full text Add to dashboard Cite

Transarterial Radioembolization (TARE) is an emerging therapy for the management of hepatocellular carcinoma (HCC). Radioactive Y90 can be loaded onto glass or resin microparticles for intra-arterial selective internal radiation therapy. TARE is a multistage procedure requiring a mapping procedure and a treatment procedure. The mapping procedure informs operators on vascular anatomy as well as potential arteriovenous shunting. Based on the device desired, goal of treatment, vascularity of the tumor and shunting, dosage can be computed for treatment day. Overall, TARE is generally a well-tolerated procedure with promising clinical outcomes with HCC for the purposes of curative therapy, downstaging, and palliation.

show abstract

Section: Safety and Efficacy Of Tarementioning

confidence: 99%

Role of Transarterial Radioembolization in Management of HCC

Badar,

Husnain,

Fung

et al. 2024

Liver Cirrhosis and Its Complications - Advances in Diagnosis and Management

View full text Add to dashboard Cite

show abstract

Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma

Hao,

Paik,

Han

et al. 2024

World J Radiol

View full text Add to dashboard Cite

As the third leading cause of cancer-related deaths worldwide, hepatocellular carcinoma (HCC) represents a significant global health challenge. This paper provides an introduction and comprehensive review of transarterial radioembolization (TARE) with Yttrium-90 (Y90), a widely performed transcatheter procedure for HCC patients who are not suitable candidates for surgery. TARE involves the targeted delivery of radioactive microspheres to liver tumors, offering a promising treatment option for managing HCC across various stages of the disease. By evaluating Y90 TARE outcomes across early, intermediate, and advanced stages of HCC, the review aims to present a thorough understanding of its efficacy and safety. Additionally, this paper highlights future research directions focusing on the potential of combination therapies with systemic and immunotherapies, as well as personalized treatments. The exploration of these innovative approaches aims to improve treatment outcomes, reduce adverse events, and provide new therapeutic opportunities for HCC patients. The review underscores the importance of ongoing research and clinical trials to optimize TARE further and integrate it into comprehensive HCC treatment paradigms.

show abstract

Post-embolization Syndrome Following Yttrium-90 Radiation Segmentectomy

Cited by 2 publications

References 19 publications

Role of Transarterial Radioembolization in Management of HCC

Role of Transarterial Radioembolization in Management of HCC

Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma

Contact Info

Product

Resources

About